company background image
ERIS logo

Eris Lifesciences NSEI:ERIS Lagerbericht

Letzter Preis

₹1.37k

Marktkapitalisierung

₹186.0b

7D

1.0%

1Y

44.5%

Aktualisiert

21 Nov, 2024

Daten

Finanzdaten des Unternehmens +

ERIS Aktienübersicht

Eris Lifesciences Limited bietet zusammen mit seinen Tochtergesellschaften inländische Markenrezepturen für chronische und subchronische Therapien in Indien an. Mehr Details

ERIS grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum4/6
Vergangene Leistung2/6
Finanzielle Gesundheit3/6
Dividenden0/6

Eris Lifesciences Limited Wettbewerber

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Eris Lifesciences
Historische Aktienkurse
Aktueller Aktienkurs₹1,366.90
52-Wochen-Hoch₹1,522.05
52-Wochen-Tief₹809.15
Beta0.33
11 Monat Veränderung7.39%
3 Monate Veränderung8.22%
1 Jahr Veränderung44.49%
33 Jahre Veränderung83.39%
5 Jahre Veränderung206.79%
Veränderung seit IPO127.25%

Aktuelle Nachrichten und Updates

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Nov 21
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Oct 15
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Recent updates

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Nov 21
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Oct 15
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28
Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

Sep 23
Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

May 26
If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 17
Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Mar 12
Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Feb 25
Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Feb 12
Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Jan 30
Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Jan 17
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Dec 30
Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Aktionärsrenditen

ERISIN PharmaceuticalsIN Markt
7D1.0%-0.2%0.3%
1Y44.5%40.5%27.3%

Rendite im Vergleich zur Industrie: ERIS übertraf die Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 40.5 erzielte.

Rendite vs. Markt: ERIS übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 27.3 erzielte.

Preisvolatilität

Is ERIS's price volatile compared to industry and market?
ERIS volatility
ERIS Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.1%
10% most volatile stocks in IN Market9.2%
10% least volatile stocks in IN Market4.0%

Stabiler Aktienkurs: ERIS hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: ERISDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
20073,620Amit Bakshiwww.eris.co.in

Eris Lifesciences Limited bietet zusammen mit seinen Tochtergesellschaften inländische Markenpräparate für chronische und subchronische Therapien in Indien an. Das Unternehmen bietet verschiedene Markenpräparate in verschiedenen therapeutischen Bereichen an, wie Anti-Diabetes, Herz-Kreislauf, Ernährung, Dermatologie, Neurowissenschaften, Gynäkologie, Nephrologie und Onkologie sowie zentrales Nervensystem, Frauengesundheit und Vitamine/Mineralien/Nährstoffe. Das Unternehmen bietet auch Dienstleistungen für die Patientenversorgung an, darunter ambulante Blutdruckmessung, ambulante Elektrokardiogrammmessung, kontinuierliches Glukoseüberwachungssystem, Schlafstudien und Lösungen für die Schwangerenvorsorge.

Eris Lifesciences Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Eris Lifesciences im Vergleich zum Marktanteil des Unternehmens?
ERIS grundlegende Statistiken
Marktanteil₹186.04b
Gewinn(TTM)₹3.48b
Umsatz(TTM)₹24.85b

53.4x

Kurs-Gewinn-Verhältnis

7.5x

Kurs-Umsatz-Verhältnis

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ERIS Gewinn- und Verlustrechnung (TTM)
Einnahmen₹24.85b
Kosten der Einnahmen₹5.90b
Bruttogewinn₹18.95b
Sonstige Ausgaben₹15.47b
Umsatz₹3.48b

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)25.60
Bruttomarge76.25%
Nettogewinnspanne14.02%
Schulden/Eigenkapital-Verhältnis84.8%

Wie hat sich ERIS auf lange Sicht entwickelt?

Historische Performance und Vergleiche